Céfiméca acquired by Oury Medical
Context
The acquisition of Céfiméca by Oury Medical represents a strategic consolidation within the French orthopedic and spinal medical device market. This transaction is the fifth build-up operation completed by Oury Medical in three years, following a platform strategy initiated by its lead investors. The primary rationale behind the deal is the creation of a comprehensive "One-Stop-Shop" offering for global orthopedic clients, combining Céfiméca’s specialized expertise in precision implants with Oury Medical’s established strength in surgical instrumentation. By integrating Céfiméca’s two production sites, the enlarged group reaches a critical mass of five manufacturing facilities and over 400 employees (combined), significantly enhancing its industrial capacity. The deal aims to improve market competitiveness by reducing lead times and offering a more integrated value chain, transitioning from a traditional supplier role to a strategic partnership model. The integration of Céfiméca’s high-value implant range specifically addresses the group's objective to master both the tools and the permanent devices used in joint and spinal procedures.
Céfiméca, which reported an EBITDA margin of [members only] in 2024, is valued in this transaction at an EV/EBITDA multiple of [members only].
-> Deep-dive in Healthcare & Pharma market trends
Target
Céfiméca is a specialized manufacturer of high-precision surgical instruments and orthopedic implants. Based in La Talaudière, near Saint-Étienne, the company supports a broad client base from the prototyping phase through to serial production for various joint applications. Its technical expertise centers on precision mechanics, allowing for the creation of both standard and custom instrumentation used in orthopedic and spinal surgeries. The business model is built upon high quality standards and regulatory compliance, maintaining two production sites to ensure industrial reliability. By focusing on the convergence of complex mechanical engineering and medical requirements, Céfiméca serves as a critical supplier for major global players in the healthcare sector, particularly those requiring specialized implant capabilities and technical depth in spinal surgery solutions.
Ent. Value
[members only]
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (EUR)
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 06/2026 | MOTION EQUITY PARTNERS | POLARIS | FRANCE | Nutrition & Dietary Supplements |
| 05/2026 | STRYKER | AMPLITUDE VASCULAR SYSTEMS | UNITED STATES | Medical Devices |
| 04/2026 | ASTORG | THERMO FISHER MICROBIOLOGY | UNITED STATES | Diagnostic Equipment |
| 04/2026 | HALMA | SURGISTAR | UNITED STATES | Medical Devices |
| 04/2026 | AMERICAN INDUSTRIAL PARTNERS AIP | AVANOS MEDICAL | UNITED STATES | Medical Consumables |
| 04/2026 | GILEAD SCIENCES | ARCELLX | UNITED STATES | R&D Biotech |
| 04/2026 | FINE FOODS & PHARMACEUTICALS | SOFAR | ITALY | CDMO |
| 04/2026 | FOR TALENTS / UI INVESTISSEMENT / GENEO | NEFTYS PHARMA | FRANCE | Animal Health |
| 04/2026 | DEVYSER DIAGNOSTICS | CYBERGENE | SWEDEN | Diagnostic Equipment |
| 04/2026 | REVENIO GROUP CORPORATION | VISIONIX INTERNATIONAL | FRANCE | Diagnostic Equipment |
REFERENCES
Revenue range: REV €5–25M
EBITDA range: €0–5M
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Céfiméca by Oury Medical are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: céfiméca
FAQ
What transaction does this page cover?
What were Céfiméca’s revenue and EBITDA at the time of the deal?
What sources support the information on this transaction?
What is mynth?